Last reviewed · How we verify
Etocox — Competitive Intelligence Brief
marketed
etoricoxib
Mitogen-activated protein kinase 14, Prostaglandin E2 receptor EP2 subtype, Prostaglandin G/H synthase 1
Pain
Small molecule
Live · refreshed every 30 min
Target snapshot
Etocox (ETORICOXIB).
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Etocox TARGET | ETORICOXIB | marketed | etoricoxib | Mitogen-activated protein kinase 14, Prostaglandin E2 receptor EP2 subtype, Prostaglandin G/H synthase 1 | 2002-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (etoricoxib class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Etocox CI watch — RSS
- Etocox CI watch — Atom
- Etocox CI watch — JSON
- Etocox alone — RSS
- Whole etoricoxib class — RSS
Cite this brief
Drug Landscape (2026). Etocox — Competitive Intelligence Brief. https://druglandscape.com/ci/etoricoxib. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab